The pharmaceutical field is witnessing a important shift in blood sugar treatment with the arrival of GLP-1 transdermal devices. These revolutionary vehicles offer a potentially simple choice to subcutaneous injections for individuals managing diabetes mellitus type 2. By circumventing the need for frequent needles, GLP-1 skin devices promise to en